Servicio de Hematología Clínica, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Badalona; Institut de Recerca Contra la Leucèmia Josep Carreras, Universidad Autónoma de Barcelona, Barcelona, España.
Servicio de Hematología Clínica, Institut Català d'Oncologia-Hospital Germans Trias i Pujol, Badalona; Institut de Recerca Contra la Leucèmia Josep Carreras, Universidad Autónoma de Barcelona, Barcelona, España.
Med Clin (Barc). 2021 Oct 8;157(7):325-328. doi: 10.1016/j.medcli.2020.07.033. Epub 2020 Oct 22.
Gemtuzumab ozogamicin (GO) is a monoclonal antibody with significant activity in CD33+acute myeloid leukaemia (AML). At doses of 9mg/m, its benefit was limited by hepatotoxicity and sinusoidal obstruction syndrome (SOS). Fractionated doses improved toxicity without compromising efficacy. We evaluated the efficacy and the toxicity of low doses of GO.
Twenty-four patients with AML received 3mg/m of GO as a part of the induction or reinduction therapy.
Fourteen patients diagnosed with de novo AML and 10 patients with relapsed or refractory (R/R) AML received GO as a part of the induction or reinduction therapy. Three and no cases of hepatotoxicity were observed, respectively. Thirteen patients received a subsequent haematopoietic stem cell transplantation (HSCT) after GO therapy. Hepatotoxicity was observed in 2 patients and no SOS was observed in any patient.
The administration of low dose GO is feasible and does not have impact on subsequent HSCT outcome. Although some degree of hepatotoxicity was observed, there were no cases of SOS, either before or after HSCT.
吉妥珠单抗奥佐米星（GO）是一种针对 CD33+急性髓系白血病（AML）具有显著活性的单克隆抗体。在 9mg/m 的剂量下，其疗效受到肝毒性和窦状隙阻塞综合征（SOS）的限制。分次剂量可改善毒性而不影响疗效。我们评估了低剂量 GO 的疗效和毒性。
24 例 AML 患者接受 3mg/m 的 GO 作为诱导或再诱导治疗的一部分。
14 例初诊 AML 患者和 10 例复发/难治性（R/R）AML 患者接受 GO 作为诱导或再诱导治疗的一部分。分别观察到 3 例和无例肝毒性。13 例患者在 GO 治疗后接受了后续造血干细胞移植（HSCT）。2 例患者观察到肝毒性，任何患者均未观察到 SOS。
GO 的低剂量给药是可行的，并且不会对后续 HSCT 结果产生影响。尽管观察到一定程度的肝毒性，但在 HSCT 前后均未观察到 SOS。
